Show simple item record

dc.contributor.authorvan den Bent, M*
dc.contributor.authorBaumert, B*
dc.contributor.authorErridge, S*
dc.contributor.authorVogelbaum, M*
dc.contributor.authorNowak, A*
dc.contributor.authorSanson, M*
dc.contributor.authorBrandes, A*
dc.contributor.authorClement, P*
dc.contributor.authorBaurain, J*
dc.contributor.authorMason, W*
dc.contributor.authorWheeler, H*
dc.contributor.authorChinot, O*
dc.contributor.authorGill, S*
dc.contributor.authorGriffin, M*
dc.contributor.authorBrachman, D*
dc.contributor.authorTaal, W*
dc.contributor.authorRudà, R*
dc.contributor.authorWeller, M*
dc.contributor.authorMcBain, Catherine A*
dc.contributor.authorReijneveld, J*
dc.contributor.authorEnting, R*
dc.contributor.authorWeber, D*
dc.contributor.authorLesimple, T*
dc.contributor.authorClenton, S*
dc.contributor.authorGijtenbeek, A*
dc.contributor.authorPascoe, S*
dc.contributor.authorHerrlinger, U*
dc.contributor.authorHau, P*
dc.contributor.authorDhermain, F*
dc.contributor.authorvan Heuvel, I*
dc.contributor.authorStupp, R*
dc.contributor.authorAldape, K*
dc.contributor.authorJenkins, R*
dc.contributor.authorDubbink, H*
dc.contributor.authorDinjens, W*
dc.contributor.authorWesseling, P*
dc.contributor.authorNuyens, S*
dc.contributor.authorGolfinopoulos, V*
dc.contributor.authorGorlia, T*
dc.contributor.authorWick, W*
dc.contributor.authorKros, J*
dc.date.accessioned2017-09-08T11:34:31Z
dc.date.available2017-09-08T11:34:31Z
dc.date.issued2017-08-08
dc.identifier.citationInterim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. 2017 Lanceten
dc.identifier.issn1474-547X
dc.identifier.pmid28801186
dc.identifier.doi10.1016/S0140-6736(17)31442-3
dc.identifier.urihttp://hdl.handle.net/10541/620551
dc.description.abstractThe role of temozolomide chemotherapy in newly diagnosed 1p/19q non-co-deleted anaplastic gliomas, which are associated with lower sensitivity to chemotherapy and worse prognosis than 1p/19q co-deleted tumours, is unclear. We assessed the use of radiotherapy with concurrent and adjuvant temozolomide in adults with non-co-deleted anaplastic gliomas.
dc.language.isoenen
dc.rightsArchived with thanks to Lancet (London, England)en
dc.titleInterim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.en
dc.typeArticleen
dc.contributor.departmentNeuro-Oncology Unit, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlandsen
dc.identifier.journalLanceten
html.description.abstractThe role of temozolomide chemotherapy in newly diagnosed 1p/19q non-co-deleted anaplastic gliomas, which are associated with lower sensitivity to chemotherapy and worse prognosis than 1p/19q co-deleted tumours, is unclear. We assessed the use of radiotherapy with concurrent and adjuvant temozolomide in adults with non-co-deleted anaplastic gliomas.


Files in this item

This item appears in the following Collection(s)

Show simple item record